Tags

Type your tag names separated by a space and hit enter

The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil.
Lipids Health Dis 2017; 16(1):16LH

Abstract

BACKGROUND

A commonly used measure to reflect the intake of the long-chain omega-3 fatty acids EPA and DHA is the omega-3 index, defined as the sum of EPA + DHA as % of total fatty acids in erythrocyte membrane. When the omega-3 index changes it follows that the relative fractions of other fatty acids in the membrane are also changed. In the present study, increasing doses of a preparation of omega-3 rich phospholipids extracted from krill oil were administered orally to non-human primates for 12 weeks and the time course of EPA, DHA and 22 other fatty acids in erythrocytes was determined bi-weekly during treatment and for 8 weeks after cessation of treatment. Plasma concentrations of six endocannabinoid-type mediators being downstream metabolites of some fatty acids analyzed in erythrocytes were also determined.

METHODS

Six diabetic, dyslipidemic non-human primates were included, three in a vehicle control group and three being treated with the omega-3 rich phospholipid preparation. The vehicle control and test items were given daily by gavage and the test item doses were 50, 150 and 450 mg phospholipids/kg/day. Each dose level was given for four weeks. Blood was sampled at baseline and thereafter bi-weekly. Fatty acids were determined in erythrocytes by methylation followed by gas-chromatography. Endocannabinoids and endocannabinoid-like mediators were analyzed in plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.

RESULTS

The treatment resulted in a dose-related increase in the fraction of EPA and DHA in erythrocyte membranes and a dose-related decrease of other poly-unsaturated fatty acids, in particular omega-6 polyunsaturated fatty acids. Erythrocyte concentrations of saturated fatty acids remained unchanged throughout the experiment. Plasma concentrations of endocannabinoids and endocannabinoid-like mediators changed accordingly as those being downstream arachidonic acid decreased, downstream of the saturated palmitic and oleic acids remained unchanged while a downstream EPA metabolite increased.

CONCLUSION

Increasing the omega-3 index by administering an omega-3 rich phospholipid extracted from krill oil did not alter the ratio of unsaturated vs. saturated fatty acids in the erythrocyte membranes but only the relative concentrations of unsaturated fatty acids, in particular unsaturated omega-6 fatty acids. Concentrations of saturated fatty acids remained unchanged.

Authors+Show Affiliations

Aker Biomarine Antarctic AS, Oksenoyveien 10, N-1366, Lysaker, Norway. petter-arnt.hals@akerbiomarine.com.Crown Bioscience (Taicang) Inc., Science and Technology Park, 6 Beijing West Road, Taicang, Jiangsu Province, People's Republic of China.Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, NA, Italy.Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, NA, Italy.Crown Bioscience (Taicang) Inc., Science and Technology Park, 6 Beijing West Road, Taicang, Jiangsu Province, People's Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28107816

Citation

Hals, Petter-Arnt, et al. "The Time Course of Erythrocyte Membrane Fatty Acid Concentrations During and After Treatment of Non-human Primates With Increasing Doses of an Omega-3 Rich Phospholipid Preparation Derived From Krill-oil." Lipids in Health and Disease, vol. 16, no. 1, 2017, p. 16.
Hals PA, Wang X, Piscitelli F, et al. The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. Lipids Health Dis. 2017;16(1):16.
Hals, P. A., Wang, X., Piscitelli, F., Di Marzo, V., & Xiao, Y. F. (2017). The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. Lipids in Health and Disease, 16(1), p. 16. doi:10.1186/s12944-017-0414-9.
Hals PA, et al. The Time Course of Erythrocyte Membrane Fatty Acid Concentrations During and After Treatment of Non-human Primates With Increasing Doses of an Omega-3 Rich Phospholipid Preparation Derived From Krill-oil. Lipids Health Dis. 2017 Jan 21;16(1):16. PubMed PMID: 28107816.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. AU - Hals,Petter-Arnt, AU - Wang,Xiaoli, AU - Piscitelli,Fabiana, AU - Di Marzo,Vincenzo, AU - Xiao,Yong-Fu, Y1 - 2017/01/21/ PY - 2016/10/06/received PY - 2017/01/11/accepted PY - 2017/1/22/entrez PY - 2017/1/22/pubmed PY - 2017/5/16/medline KW - DHA KW - EPA KW - Endocannabinoids KW - Long-chain omega-3 fatty acids KW - Omega-3 index KW - Phospholipids SP - 16 EP - 16 JF - Lipids in health and disease JO - Lipids Health Dis VL - 16 IS - 1 N2 - BACKGROUND: A commonly used measure to reflect the intake of the long-chain omega-3 fatty acids EPA and DHA is the omega-3 index, defined as the sum of EPA + DHA as % of total fatty acids in erythrocyte membrane. When the omega-3 index changes it follows that the relative fractions of other fatty acids in the membrane are also changed. In the present study, increasing doses of a preparation of omega-3 rich phospholipids extracted from krill oil were administered orally to non-human primates for 12 weeks and the time course of EPA, DHA and 22 other fatty acids in erythrocytes was determined bi-weekly during treatment and for 8 weeks after cessation of treatment. Plasma concentrations of six endocannabinoid-type mediators being downstream metabolites of some fatty acids analyzed in erythrocytes were also determined. METHODS: Six diabetic, dyslipidemic non-human primates were included, three in a vehicle control group and three being treated with the omega-3 rich phospholipid preparation. The vehicle control and test items were given daily by gavage and the test item doses were 50, 150 and 450 mg phospholipids/kg/day. Each dose level was given for four weeks. Blood was sampled at baseline and thereafter bi-weekly. Fatty acids were determined in erythrocytes by methylation followed by gas-chromatography. Endocannabinoids and endocannabinoid-like mediators were analyzed in plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. RESULTS: The treatment resulted in a dose-related increase in the fraction of EPA and DHA in erythrocyte membranes and a dose-related decrease of other poly-unsaturated fatty acids, in particular omega-6 polyunsaturated fatty acids. Erythrocyte concentrations of saturated fatty acids remained unchanged throughout the experiment. Plasma concentrations of endocannabinoids and endocannabinoid-like mediators changed accordingly as those being downstream arachidonic acid decreased, downstream of the saturated palmitic and oleic acids remained unchanged while a downstream EPA metabolite increased. CONCLUSION: Increasing the omega-3 index by administering an omega-3 rich phospholipid extracted from krill oil did not alter the ratio of unsaturated vs. saturated fatty acids in the erythrocyte membranes but only the relative concentrations of unsaturated fatty acids, in particular unsaturated omega-6 fatty acids. Concentrations of saturated fatty acids remained unchanged. SN - 1476-511X UR - https://www.unboundmedicine.com/medline/citation/28107816/The_time_course_of_erythrocyte_membrane_fatty_acid_concentrations_during_and_after_treatment_of_non_human_primates_with_increasing_doses_of_an_omega_3_rich_phospholipid_preparation_derived_from_krill_oil_ L2 - https://lipidworld.biomedcentral.com/articles/10.1186/s12944-017-0414-9 DB - PRIME DP - Unbound Medicine ER -